Fig. 4

PepN-pretreatment expands CD11c^high macrophages that were partially derived from CD11c^int macrophages. a, b ELISA of cytokine CCL2 in lung homogenates (n = 5–7). c Percentage and absolute number of macrophages (F4/80⁺CD11c^high/int/−) in lungs of mice treated with PepN on days 0, 3 and 6. Macrophage staining was quantified by flow cytometry two days following each treatment (n = 4–5). d Schematic diagram of the generation of mice bone marrow chimeras with thoracic shielding and busulfan and PepN-treatments as indicated. e, f Representative dot plots reflecting BM-derived (%) and tissue-resident (%) macrophages in the lung of chimeric mice 8 weeks after irradiation and bone marrow transfer and 7 days after i.n. PepN treatment (50 μg). Statistical analysis by a two-tailed student’s t test (b), one-way ANOVA with Tukey’s multiple-comparison test (a–c). Data pooled from at least 3–4 independent experiments (e, f). Data are represented as mean ± SD (a–c). ns, not significant